SEARCH

SEARCH BY CITATION

References

  • 1
    Brown JM, Bradly G. Wouters. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999: 59: 13919.
  • 2
    Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997: 3: 91721.
  • 3
    Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999: 17: 21004.
  • 4
    Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998: 58: 50714.
  • 5
    Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004: 10: 324550.
  • 6
    Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998: 58: 531520.
  • 7
    Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998: 396: 5804.
  • 8
    Ferrira CG, Tolis C, Giaconne G. p53 and chemosensitivity. Ann Oncol 1999: 10: 101121.
  • 9
    Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994: 266: 80710.
  • 10
    El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993: 75: 81725.
  • 11
    Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003: 29: 3250716.
  • 12
    Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999: 18: 59548.
  • 13
    Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999: 274: 2967782.
  • 14
    Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002: 277: 324757.
  • 15
    Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB. et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002: 21: 261322.
  • 16
    Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2003: 2: 48893.
  • 17
    Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000: 60: 28059.
  • 18
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001: 411: 4948.
  • 19
    Brantl S. Antisense-RNA regulation and RNA interference. Biophysica Acta 2002: 1575: 1525.
  • 20
    Fukumoto H, Nishio K, Ohta S, Hanai N, Fukuoka K, Ohe Y, Sugihara K, Kodama T, Saija N. et al. Effect of chimeric antiganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo. Int J Cancer 1999: 82: 75964.
  • 21
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983: 65: 5563.
  • 22
    Hensel CH, Xiang RH, Sakaguchi AY, Naylor SL. Use of the Single Strand Conformation Polymorphism Technique and PCR to Detect p53 Gene Mutations in Small Cell Lung Cancer. Oncogene 1991: 6: 106771.
  • 23
    Mitsudomi T, Steinberg SM, Nau MM, Carbone D, Damico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. p53 Gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992: 7: 17180.
  • 24
    Kashii T, Mizushima Y, Monno S, Nakagawa K, Kobayashi M. Gene analysis of K-ras, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain Reaction/Single-Strand conformation polymorphism method. J Cancer Res Clin Oncol 1994: 120: 1438.
  • 25
    Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinogen 1997: 19: 24353.
  • 26
    Fujita T, Kiyama M, Tomizawa Y, Kohno T, Yokota J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol 1999: 15: 92734.
  • 27
    Yoshida M, Suzuki T, Komiya T, Hatashita E, Nishio K, Kazuhiko N, Nakagawa K, Fukuoka M. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. Int J Cancer 2001: 94: 4327.
  • 28
    Tamura K, Southwick EC, Kerns J, Rosi K, Carr BI, Wilcox C, Lazo JS. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res 2000: 60: 131725.
  • 29
    Sgonc R, Gruber J. Apoptosis detection: an overview. Exp Gerontol 1998: 33: 52533.
  • 30
    Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998: 58: 180812.
  • 31
    Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002: 86: 88692.
  • 32
    Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004: 23: 814653.
  • 33
    Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003: 63: 2305.
  • 34
    Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998: 273: 1117782.
  • 35
    Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001: 98: 63540.
  • 36
    Mehdi Mesri, Nathan R. Wall, Jia Li, Richard W. Kim, Dario C. Altieri. Cancer gene therapy using a suvivin mutant adenovirus. J Clin Inv 2001: 108: 98190.